The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer

被引：0

作者：

Dent, S. ^{[1
,2
]}

Verma, Sh. ^{[2
]}

Latreille, J. ^{[14
]}

Rayson, D. ^{[3
,4
,5
]}

Clemons, M. ^{[6
]}

Mackey, J. ^{[7
]}

Verma, Su ^{[8
,9
]}

Lemieux, J. ^{[10
]}

Provencher, L. ^{[11
]}

Chia, S. ^{[12
]}

Wang, B. ^{[13
]}

Pritchard, K. ^{[8
,9
]}

机构：

[1] Ottawa Hosp, Ctr Canc, Gen Div, Ottawa, ON K1H 8L6, Canada

[2] Univ Ottawa, Ottawa, ON, Canada

[3] Univ Sherbrooke, Longueuil, PQ, Canada

[4] Atlantic Clin Canc Res Unit, Halifax, NS, Canada

[5] QEII Canc Care Program, Halifax, NS, Canada

[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[7] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[8] Univ Toronto, Toronto, ON, Canada

[9] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[10] Univ Quebec, Ctr Hosp, Ctr Rech, Quebec City, PQ, Canada

[11] Hop St Sacrement, Quebec City, PQ, Canada

[12] British Columbia Canc Agcy Vancouver Ctr, Vancouver, BC, Canada

[13] Remedy Commun Ltd, Toronto, ON, Canada

[14] Reseau Canc Monteregie, Longueuil, PQ, Canada

来源：

CURRENT ONCOLOGY | 2009年 / 16卷 / 04期

关键词：

Metastatic breast cancer; trastuzumab; treatment beyond progression; re-treatment; HER2-targeted therapy; HERCEPTIN-INDUCED INHIBITION; DISEASE PROGRESSION; MONOCLONAL-ANTIBODY; TRASTUZUMAB; HER-2; SURVIVAL; SAFETY; AKT; COMBINATION; EXPERIENCE;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER 2), was the first HER2-targeted therapy that clearly demonstrated a significant clinical benefit for women with HER2-overexpressing metastatic breast cancer (MBC). However, in recent years it has become increasingly apparent that, when trastuzumab is used in the first-line setting in combination with chemotherapy, most women eventually develop progressive disease. Determining the treatment options available to women who have progressed while on trastuzumab therapy has been hampered by a paucity of high-quality published data. In addition, with the standard use of trastuzumab in the adjuvant setting (for eligible HER2-positive patients), the role of anti-HER2 agents for patients who experience a breast cancer relapse has become a clinically relevant question. This manuscript reviews current available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents in two key MBC indications: Treatment for women with HER2-positive MBC progressing on trastuzumab (that is, treatment beyond progression) Treatment for women with HER2-positive MBC recurring following adjuvant trastuzumab (that is, re-treatment) The suggestions set out here will continue to evolve as data and future trials with trastuzumab and other HER2-targeted agents emerge.

引用

页码：235 / 245

页数：11

共 68 条

[1] Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer:: our long-term clinical experience (GOIM study) [J].

Adamo, V. ;

Franchina, T. ;

Adamo, B. ;

Ferraro, G. ;

Rossello, R. ;

Sacca, M. Maugeri ;

Scibilia, C. ;

Valerio, M. R. ;

Russo, A. .

ANNALS OF ONCOLOGY, 2007, 18 :11-15

[2] Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study [J].

Antoine, E. C. ;

Extra, J. M. ;

Vincent-Salomon, A. ;

Bergougnoux, L. ;

Campana, F. ;

Namer, M. .

EJC SUPPLEMENTS, 2007, 5 (04) :213-213

[3] Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[4]

Bachelot T, 2007, J CLIN ONCOL, V25

[5] Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer [J].

Bartsch, Rupert ;

Wenzel, Catharina ;

Altorjai, Gabriela ;

Pluschnig, Ursula ;

Rudas, Margaretha ;

Mader, Robert M. ;

Gnant, Michael ;

Zielinski, Christoph C. ;

Steger, Guenther G. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3853-3858

[6]

BASELGA J, 2007, P AM SOC CLIN ONCOL, V25

[7] Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data [J].

Belli, R. ;

Feng-Yi, F. ;

Barrios, C. H. ;

Yu, S. Y. ;

Lopez, R. I. ;

Khasanov, R. ;

Semigiazov, V. ;

Feyereislova, A. ;

Muehlbauer, S. ;

Jassem, J. .

EJC SUPPLEMENTS, 2007, 5 (04) :220-220

[8] Acetylation and chromosomal functions [J].

Cheung, WL ;

Briggs, SD ;

Allis, CD .

CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (03) :326-333

[9]

Choi YH., 2009, ANN ONCOL

[10] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

← 1 2 3 4 5 6 7 →